Skip to main content
Xbrane Biopharma logo

Xbrane Biopharma — Investor Relations & Filings

Ticker · XBRANE ISIN · SE0007789409 LEI · 5493008DKD05APTKQO39 ST Manufacturing
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-05-05 Declaration of Voting R…
Country SE Sweden
Listing ST XBRANE

About Xbrane Biopharma

https://xbrane.com/en/

Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma i Xbrane Biopharma AB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release dated May 5, 2026, reporting on the Annual General Meeting (AGM) of Xbrane Biopharma AB. It details decisions made at the AGM, including approval of financial statements, discharge of board and CEO, election of board members and auditors, approval of remuneration report, adoption of remuneration guidelines, and authorization for share issuance. The document is a summary communication of the AGM outcomes rather than the full AGM materials or presentations. It is not a full annual report or financial report but a formal announcement of AGM decisions. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4353 characters, which is consistent with a detailed announcement but not a full report or presentation.
2026-05-05 English
Announcement from the annual general meeting in Xbrane Biopharma AB
AGM Information Classification · 95% confidence The document is a press release dated 5 May 2026, announcing the resolutions passed at the Annual General Meeting (AGM) of Xbrane Biopharma AB. It includes details such as adoption of income statement and balance sheet, allocation of profit, discharge from liability, election of board members and auditors, approval of remuneration report, adoption of remuneration guidelines, and authorization for the board to issue shares. The content is typical of an AGM announcement summarizing the meeting outcomes rather than the full AGM materials or the annual report itself. The document length is 4894 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-05-05 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January – March 2026' and contains detailed financial data for the first quarter of 2026, including revenue, EBITDA, R&D costs, earnings per share, cash flow, and other financial metrics. It also includes a CEO letter discussing business operations, product portfolio updates, and financial position. The presence of comprehensive financial statements and analysis for a quarter, along with management commentary, clearly identifies this as a quarterly financial report. The document length is substantial (15,000 characters), and it contains actual financial data rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-05 English
Valuation expert Venture Valuation provides external valuation of Xdivane program
Regulatory Filings Classification · 95% confidence The document is a press release dated May 5, 2026, from Xbrane Biopharma announcing an external valuation of their Xdivane program by Venture Valuation. It provides detailed assumptions and valuation figures but does not contain financial statements, regulatory filings, or management discussion of financial results. The document is relatively short (3255 characters) and serves as an announcement of a valuation rather than a comprehensive financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement either, as it does not mention the release or availability of a report. The content is best classified as a general regulatory announcement or miscellaneous filing that does not fit other categories, which corresponds to Regulatory Filings (RNS).
2026-05-05 English
Värderingsexperten Venture Valuation tillhandahåller extern värdering av Xdivane-programmet
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Xbrane Biopharma has engaged an external valuation expert, Venture Valuation AG, to provide an independent valuation of its Xdivane program. The text includes detailed assumptions and valuation figures but does not contain actual financial statements or comprehensive financial performance data. It is a communication about a valuation update rather than a formal financial report or regulatory filing. The document length is 3403 characters, which is relatively short and consistent with a press release or announcement. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is also not a certification, voting result, or management change announcement. Therefore, the best fitting category is a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2026-05-05 English
Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities
Capital/Financing Update Classification · 95% confidence The document is a press release dated May 5, 2026, announcing a revised financing arrangement between Xbrane Biopharma and its partner Intas regarding the development activities of a biosimilar candidate, Xdivane. The content focuses on changes to the financing terms and responsibilities under an existing license agreement. There are no financial statements, detailed financial performance data, or comprehensive management analysis present. The document is an update on financing terms rather than a full financial report or earnings release. It is not a regulatory filing or certification, nor does it announce voting results, board changes, or legal proceedings. The document fits best as a Capital/Financing Update (CAP) because it provides information on financing arrangements and capital structure changes related to development activities.
2026-05-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.